Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

周三，贝尔德(Baird)维持了对Exact Sciences(NASDAQ:EXAS)股票的优于大盘评级，但将其目标价从70.00美元下调至67.00美元。这一调整是在该公司报告第三季度收入低于预期并大幅下调2024年收入指引之后做出的。下调主要是由于筛查业务趋势弱于预期。 Exact Sciences在8月至10月期间经历了Cologuard产品的异常订单模式，加上商业执行挑战、飓风影响以及销 ...

EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international ...

周三，Benchmark分析师Bruce Jackson修正了Exact Sciences（NASDAQ:EXAS）的股票目标价，将其从之前的$67下调至$65，同时重申了对该股的买入评级。此次调整是在公司第三季度财报不及预期，并下调2024年剩余月份收入预测之后做出的。

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 and keeps an Overweight rating on the shares. The firm notes Exact Sciences reported a ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

(2) Represents stock-based compensation expense and 401(k) match expense. The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common ...

Exact Sciences' Q3 earnings report has led to a ~25% drop in its share price, due to a slight guidance cut and narrow revenue miss. Despite impressive historic revenue growth, Exact faces ...